Purchase Order 75N93018P01316

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,292.25 on August 29, 2019, for antibodies with a completion date of September 30, 2019. Work is performed in San Diego, California. The order is a firm fixed-price acquisition with no set-aside applied.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $19,987.50 on August 24, 2020, for antibodies. Performance is located in San Diego, California with completion scheduled for September 23, 2020. This firm fixed-price acquisition carries no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $102,869 on September 16, 2019. The order covers antibodies and related biomedical reagents. Place of performance is San Diego, California. The ultimate completion date is October 16, 2019. The requirement originated from a pre-solicitation posted September 11, 2019, with award on the same date as the stated due date.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for COVID-19 reagents with a ceiling value of $26,145.00, effective April 9, 2021. Performance is located in San Diego, California, with an ultimate completion date of May 7, 2021. The order is firm fixed price with no small business set-aside.</p>

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a $56,762.00 firm-fixed-price purchase order to Biolegend, Inc. for the supply of various biological research products, including Alexa Fluor 700 anti-human IFN-γ and several Brilliant Violet-labeled antibodies for human cellular markers. This acquisition was processed under Simplified Acquisition Procedures without a small business set-aside. Biolegend, a...

This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH), to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The $16,199.95 contract is for the delivery of BIOLEGEND antibodies to support NIAID's research initiatives, which may include studies related to COVID-19, immunology, and other disease areas. The contract does not...